SINOVAC BIOTECH LTD's ticker is SVA and the CUSIP is P8696W104. A total of 33 filers reported holding SINOVAC BIOTECH LTD in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $115,000 | -21.2% | 15,000 | -23.5% | 0.00% | – |
| Q2 2018 | $146,000 | -40.4% | 19,600 | -31.2% | 0.00% | – |
| Q1 2018 | $245,000 | +23.7% | 28,500 | +13.5% | 0.00% | – |
| Q4 2017 | $198,000 | -17.8% | 25,100 | -26.6% | 0.00% | – |
| Q3 2017 | $241,000 | +201.2% | 34,193 | +189.8% | 0.00% | – |
| Q2 2017 | $80,000 | +3.9% | 11,800 | -9.8% | 0.00% | – |
| Q3 2016 | $77,000 | -85.7% | 13,084 | -88.0% | 0.00% | -100.0% |
| Q1 2015 | $539,000 | -34.0% | 108,652 | -30.5% | 0.00% | 0.0% |
| Q4 2014 | $817,000 | +8.2% | 156,237 | -0.5% | 0.00% | 0.0% |
| Q3 2014 | $755,000 | -21.2% | 157,038 | -7.5% | 0.00% | 0.0% |
| Q2 2014 | $958,000 | +3.5% | 169,762 | +32.0% | 0.00% | 0.0% |
| Q1 2014 | $926,000 | +1282.1% | 128,577 | +1066.8% | 0.00% | – |
| Q4 2013 | $67,000 | -53.1% | 11,020 | -53.8% | 0.00% | – |
| Q3 2013 | $143,000 | +62.5% | 23,860 | +6.9% | 0.00% | – |
| Q2 2013 | $88,000 | – | 22,326 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,718,735 | $340,500,000 | 6.32% |
| Vivo Capital, LLC | 5,900,000 | $38,173,000 | 4.21% |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2,042 | 0.72% |
| Yorktown Management & Research Co Inc | 74,893 | $485,000 | 0.63% |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $259,000 | 0.00% |
| Renaissance Technologies | 2,375,841 | $1,537,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 1,687 | $11,000 | 0.00% |
| NORTHERN TRUST CORP | 13,787 | $55,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 412 | $27,000 | 0.00% |